Best Healthcare Equipment Companies To Own For 2014

In the last decade, we've been through five distinct boom and bust periods. Surge, crash, surge, crash, surge.

I asked Art Cashin, a 50-year veteran of the New York Stock Exchange, what the mood has been like on the trading floor during these wild periods. Here's what he had to say (transcript follows):

Morgan Housel: In the past 13 years, we've been through the top of the dot-com bubble in 2000 and then the bottom lows in March 2009 and the financial crisis. What was the mood like on the New York Stock Exchange during those two periods? Was there a sense that this was real or was it obvious that these were tops and bottoms going on? What are the emotions like down there?

Arthur Cashin: Well you know, no one ever quite rings a bell at the top. It would be very convenient and we would all know to just step aside, but you can see some of the excesses going on. With the dot-com bubble, you began to notice that things were just not right. They had a company that sold on the Internet airline tickets. The value of that company soon grew to more than the value of all the airlines combined. Now that made absolutely no sense.

Top 10 High Dividend Companies To Own In Right Now: S&P Smallcap 600(PH)

Parker Hannifin Corporation manufactures fluid power systems, electromechanical controls, and related components worldwide. Its Industrial segment offers pneumatic and electromechanical components, and systems; filters, systems, and instruments to monitor and remove contaminants from fuel, air, oil, water, and other liquids and gases; connectors that control, transmit, and contain fluid; hydraulic components and systems for builders and users of industrial and mobile machinery and equipment; critical flow components for process instrumentation, healthcare, and ultra-high-purity applications; and static and dynamic sealing devices. This segment sells its products to original equipment manufacturers (OEMs) and their replacement markets in the manufacturing, transportation, and processing industries. The company?s Aerospace segment provides flight control systems and components, including hydraulic, electrohydraulic, electric backup hydraulic, electrohydrostatic, and electro -mechanical components for precise control of aircraft rudders, elevators, ailerons, and other aerodynamic control surfaces. It also provides electronics thermal management heat rejection systems, and single-phase and two-phase heat collection systems for radar, ISAR, and power electronics. This segment markets its products primarily to OEMs in the commercial, military, and general aviation markets, as well as to end users. Its Climate and Industrial Controls segment offers systems and components primarily for use in the mobile and stationary refrigeration, and air conditioning industry; and in fluid control applications in various industries, such as processing, fuel dispensing, beverage dispensing, and mobile emissions. This segment serves OEMs and their replacement markets. Parker-Hannifin Corporation markets its products through direct-sales employees, independent distributors, wholesalers, and sales representatives. The company was founded in 1918 and is headquartered i n Cleveland, Ohio.

Advisors' Opinion:

• [By Monica Gerson]

  Parker-Hannifin (NYSE: PH) is expected to report its Q1 earnings at $1.48 per share on revenue of $3.26 billion.

  Textron (NYSE: TXT) is estimated to report its Q3 earnings at $0.47 per share on revenue of $2.97 billion.

Best Healthcare Equipment Companies To Own For 2014: Salix Pharmaceuticals Ltd (SLXP)

Salix Pharmaceuticals, Ltd., incorporated on December 31, 2001, is a specialty pharmaceutical company dedicated to acquiring, developing and commercializing prescription drugs and medical devices used in the treatment of a variety of gastrointestinal disorders, which are those affecting the digestive tract. As of December 31, 2012, the Company�� products included XIFAXAN, MOVIPREP, APRISO, RELISTOR, OSMOPREP, SOLESTA, DEFLUX, FULYZAQ, GIAZO, METOZOLV ODT, AZASAN, ANUSOL-HC, PROCTOCORT, PEPCID, DIURIL and COLAZAL. As of December 31, 2012, its primary product candidates under development included Rifaximin, Methylnaltrexone bromide oral, Budesonide foam and Rifaximin EIR. In January 2014, Salix Pharmaceuticals, Ltd. acquired Santarus, Inc.

Xifaxan (rifaximin) tablets

Xifaxan is a gastrointestinal-specific oral antibiotic. The Food and Drug Administration ( FDA) approved Xifaxan 200 milligram for the treatment of patients 12 years of age and older with travelers��diarrhea caused by noninvasive strains of E coli. Xifaxan 550 milligram was approved by the FDA for reduction in risk of overt hepatic encephalopathy (HE), recurrence in patients 18 years of age or older.

It launched Xifaxan 200milligram in the United States and Xifaxan 550 milligram using its own direct sales force. The Company is exploring potential additional indications, formulations, clinical trials and co-promotion arrangements to capitalize on the potential for Xifaxan, including its development program in irritable bowel syndrome.

In October 2012, the USPTO declared an interference action to determine the priority of invention between Cipla�� application related to amorphous rifaximin and Solmag SpA�� application directed to amorphous rifaximin. In February 2012, the FDA posted draft bioequivalence guidance for rifaximin 550 milligram tablets. The draft guidance for rifaximin 550 milligram tablets recommends that in addition to conducting the program outlined in the FDA posted ! draft guidance document for rifaximin 200 milligram tablets discussed above, a single-dose, three-way crossover in-vivo study of fasting bioequivalence with pharmacokinetic endpoints in both fasting and fed states be performed in the 550 milligram tablets. Additionally, the guidance stipulated that the formulation of the 550 milligram strength should be proportionally similar to that of the 200 milligram strength in order to file an ANDA for approval of a generic rifaximin 550 milligram tablet for the treatment of hepatic encephalopathy.

MoviPrep (PEG 3350, sodium sulfate, sodium chloride, potassium chloride, sodium ascorbate and ascorbic acid) oral solution

MoviPrep is a patent-protected, liquid polyethylene glycol-salt, or PEG, bowel cleansing product that the FDA approved. MoviPrep is indicated for bowel cleansing prior to colonoscopy, intestinal surgery and barium enema X-ray examinations.

Apriso (mesalamine) extended-release capsules 0.375 gram

Apriso is a locally-acting aminosalicylate and is the only delayed and extended release mesalamine product approved by the FDA for once-a-day dosing for the maintenance of remission of ulcerative colitis. Apriso is designed to provide for the distribution of the active ingredient beginning in the small bowel and continuing throughout the colon. The product�� prolonged release mechanism might allow them to expand the range of treatment options for ulcerative colitis.

Relistor (methylnaltrexone bromide)

Relistor Subcutaneous Injection is indicated for the treatment of opioid-induced constipation (OIC) in patients with advanced illness who are receiving palliative care, when response to laxative therapy has not been sufficient. Relistor is approved for use in over 55 countries worldwide.

OsmoPrep and Visicol (sodium phosphate monobasic monohydrate, USP, sodium phosphate dibasic anhydrous, USP) tablets

Visicol and OsmoPrep tablets are indicated for clean! sing of t! he colon as a preparation for colonoscopy in adults 18 years of age or older. Visicol and OsmoPrep are the only, tablet bowel cleansing products approved by the FDA and marketed in the United States. OsmoPrep is a patented, second-generation tablet bowel cleansing product that the FDA approved. OsmoPrep offers potential benefits compared to Visico,l such as its lack of microcrystalline cellulose, smaller tablet size and possible lower dose administration.

Solesta

Solesta is a biocompatible tissue bulking agent, consisting of dextranomer microspheres and stabilized sodium hyaluronate. Solesta is indicated for the treatment of fecal incontinence in patients 18 years and older who have failed conservative therapy, such as diet, fiber therapy and/or anti-motility medications. It is the only injectable gel for this indication to be administered in an outpatient setting without the need for surgery or anesthesia.

Deflux

Deflux is a medical device indicated for children affected by Grades II-IV vesicoureteral reflux, a malformation of the urinary bladder that can result in severe infections of the kidneys and irreversible kidney damage. Deflux was granted premarket approval application (PMA) approval, and has been on the market in the United States.

Fulyzaq (crofelemer) delayed-release tablets

On December 31, 2012, the FDA granted marketing approval for this product, under the trade name Fulyzaq. Fulyzaq is indicated for the symptomatic relief of non-infectious diarrhea in adult patients with HIV/AIDS on anti-retroviral therapy. Fulyzaq should also be eligible for five years of marketing exclusivity from the date of FDA approval, and the product might be entitled to patent term restoration.

Giazo (balsalazide disodium) tablets

February 3, 2012, the FDA granted marketing approval for this product under the trade name Giazo. Giazo is indicated for the treatment of mildly to moderately active ulcerative col! itis in m! ale patients 18 years of age and older. It shipped Giazo to wholesalers in 2012.

Metozolv ODT (metoclopramide hydrochloride) 5 milligrams and 10 milligrams orally disintegrating tablets

METOZOLV ODT is indicated for the relief of symptomatic gastroesophageal reflux or short-term (4-12 weeks) therapy for adults with symptomatic, documented gastroesophageal reflux who fail to respond to conventional therapy and diabetic gastroparesis or the relief of symptoms in adults associated with acute and recurrent diabetic gastroparesis.

Azasan (azathioprine) tablets

Azasan is an FDA-approved drug that suppresses immune system responses and is indicated for preventing rejection of kidney transplants and treatment of severe arthritis. It launched the 75 and 100 milligrams dosage strengths of Azasan in the United States.

Anusol-HC and Proctocort (hydrocortisone) creams and suppositories

The Company acquired the right to sell Anusol-HC 2.5% (hydrocortisone USP) cream, Anusol-HC 25 milligrams (hydrocortisone acetate) rectal suppositories, Proctocort 1% (hydrocortisone USP) cream and Proctocort 30 mg (hydrocortisone acetate) rectal suppositories from King Pharmaceuticals, Inc. The two cream products are topical corticosteroids indicated for relief of the inflammatory and pruritic, or itching, manifestations of corticosteroid-responsive dermatoses. The two suppository products are indicated for use in inflamed hemorrhoids and postirradiation proctitis, as well as an adjunct in the treatment of chronic ulcerative colitis and other inflammatory conditions.

Pepcid (famotidine) for Oral Suspension and Diuril (Chlorothiazide)

Pepcid Oral Suspension is a widely known prescription pharmaceutical product indicated for several gastrointestinal indications, including the treatment of duodenal ulcer, benign gastric ulcer and gastro-esophageal reflux disease. Pepcid Oral Suspension and Diuril Oral Suspension, both liquid form! ulations ! of their solid dosage form counterparts, compete in a combined annual United States market concentrated in pediatric and hospitalized patient populations.

Colazal (balsalazide disodium) capsules

The Company launched Colazal to physicians in the United States. FDA approved Colazal for use in pediatric patients between 5 to 17 years of age with ulcerative colitis. The pediatric use of Colazal has been granted orphan drug designation. The Office of Generic Drugs, or OGD, approved three generic balsalazide capsule products.

The Company competes with GlaxoSmithKline plc, Giuliani S.p.A., Axcan Pharma, Inc., Abbott Laboratories, Warner Chilcott plc, Shire Pharmaceuticals Group plc, Pharmacia & Upjohn, Inc., Alaven Pharmaceutical LLC, Ferring Pharmaceuticals, Inc, Takeda Pharmaceutical Company Limited, Cumberland Pharmaceuticals, Inc, Prometheus Laboratories, Inc., Ranbaxy Pharmaceuticals, Ferndale Laboratories, GATE Pharmaceuticals , Nycomed , Medtronic, Inc., and Cubist Pharmaceuticals, Inc.

Advisors' Opinion:

• [By Eric Volkman]

  McGraw-Hill Financial's S&P Dow Jones Indices is making several adjustments to a pair of its signature products. On July 30 after market close, the S&P MidCap 400 will be the new home of Salix Pharmaceuticals (NASDAQ: SLXP  ) , which advances from the S&P SmallCap 600 to replace Gardner Denver (NYSE: GDI  ) . The latter company agreed to be acquired by KKR earlier this month.

• [By Lisa Levin]

  Santarus (NASDAQ: SNTS) shares surged 37.64% to touch a new 52-week high of $31.96 after Salix Pharmaceuticals (NASDAQ: SLXP) announced its plans to buy Santarus for around $2.12 billion. Santarus and Pharming also announced new data from open-label repeat treatment study with RUCONEST.

Best Healthcare Equipment Companies To Own For 2014: VOC Energy Trust(VOC)

VOC Energy Trust owns a term net profits interest of the net proceeds from production of the interests in oil and natural gas properties in the states of Kansas and Texas. It owns an 80% term net profits interest of the net proceeds on the underlying properties. As of December 31, 2009, the underlying properties produced oil from approximately 892 gross (550.2 net) wells located in 193 fields; and had total proved reserves of 13.0 million barrels of oil equivalent. The company was founded in 2010 and is based in Austin, Texas.

Advisors' Opinion:

• [By Aaron Levitt]

  VOC Energy Trust (VOC): Formed by a private energy firm, VOC owns both oil and gas wells in has wells in Kansas and Texas. The royalty trust owns an 80% net royalty on the wells on its properties. That makes a prime play on rising energy prices- no matter which fuel is doing well. VOC’s royalties will expire at the end of 2031 and yield no terminal value. Meaning shares will go to zero. Yet, VOC features a trailing yield of about�14% based on the last four payments.

Best Healthcare Equipment Companies To Own For 2014: HSBC Holdings PLC (HBC)

HSBC Holdings plc (HSBC), incorporated on January 1, 1959, is a global banking and financial services organizations. As of December 31, 2010, it provided a range of financial services to around 95 million customers through two customer groups, Personal Financial Services (PFS), including consumer finance, and Commercial Banking (CMB), and two global businesses, Global Banking and Markets (GB&M), and Global Private Banking (GPB). Its international network covers 87 countries and territories in six geographical regions; Europe, Hong Kong, Rest of Asia-Pacific, the Middle East, North America and Latin America. As of December 31, 2010, the Company had an international network of some 7,500 offices in 87 countries and territories in six geographical regions; Europe, Hong Kong, Rest of Asia-Pacific, the Middle East, North America and Latin America. PFS incorporates the Company�� consumer finance businesses, which include HSBC Finance Corporation (HSBC Finance). In April 2011, the Company closed its retail banking operation in Russia. In July 2011, the Company sold its unsecured written-off personal loan and credit card portfolio to J M Financial Asset Reconstruction Co. Pvt. Ltd. On May 20, 2012, HSBC Holdings PLC's wholly owned subsidiary HSBC Bank USA, N.A. and other wholly owned subsidiaries, sold 195 retail branches to First Niagara Bank, N.A. (First Niagara). In May 2012, the Company�� 70.03% owned subsidiary, HSBC Bank Malta plc, sold its card acquiring business to HSBC Merchant Services Ltd. In June 2012, the Company�� indirect wholly owned subsidiary, HSBC Iris Investments (Mauritius) Ltd, sold its 4.73% interest in Axis Bank Limited and 4.74% interest in Yes Bank Limited. In July 2012, its subsidiary, HSBC Europe (Netherlands B.V.), sold its 100% interest in HSBC Credit Zrt, to CentralFund Kockazati Tokealap. On March 31, 2013, Enstar Group Ltd�� subsidiary completed the acquisition from Household Insurance Group Holding Company of HSBC Insurance Company of Delaware and Household Life Insur! ance Company of Delaware, as well as its three subsidiary insurers.

The Company�� principal banking operations in Europe are HSBC Bank plc in the United Kingdom, HSBC France, HSBC Bank A.S. in Turkey, HSBC Bank Malta p.l.c., HSBC Private Bank (Suisse) S.A. and HSBC Trinkaus & Burkhardt AG. Through these operations it provides a range of banking, treasury and financial services to personal, commercial and corporate customers across Europe. HSBC�� banking subsidiaries in Hong Kong are The Hongkong and Shanghai Banking Corporation Limited and Hang Seng Bank Limited.

The Company offers a range of banking and financial services in the People�� Republic of China, mainly through its local subsidiary, HSBC Bank (China) Company Limited. It also participates indirectly in the People�� Republic of China through its four associates. Outside Hong Kong and the People�� Republic of China, it conducts business in 22 countries and territories in the Rest of Asia-Pacific region, through branches and subsidiaries of The Hongkong and Shanghai Banking Corporation, with coverage in Australia, India, Indonesia, Malaysia and Singapore.

In the Middle East, the Company has network of branches of HSBC Bank Middle East Limited, together with HSBC�� subsidiaries and associates. Its North American businesses are located in the United States, Canada and Bermuda. Operations in the United States are conducted through HSBC Bank USA, N.A., which is concentrated in New York State, and HSBC Finance, a national consumer finance company based near Chicago. HSBC Markets (USA) Inc. is the intermediate holding company of, inter alia, HSBC Securities (USA) Inc. HSBC Bank Canada and HSBC Bank Bermuda operate in their respective countries.

The Company�� operations in Latin America consists of HSBC Bank Brasil S.A.-Banco Multiplo, HSBC Mexico, S.A., HSBC Bank Argentina S.A. and HSBC Bank (Panama) S.A. In addition to banking services, it operates insurance businesses in Brazil, Mexi! co, Argen! tina, Panama and a range of smaller markets.

Personal Financial Services

PFS offers the Company�� products and services to customers based on their individual needs. Premier and Advance services are for customers who value international connectivity and benefit from its global reach and scale. It offers a range of banking products and services reflecting local requirements. In addition, it issues card globally, offering HSBC branded cards, co-branded cards with selected partners and private label (store) cards. Its customer offerings include personal banking products, including current and savings accounts, mortgages and personal loans, credit cards, debit cards and local and international payment services, and wealth management services, including insurance and investment products and financial planning services.

HSBC Premier provides preferential banking services to high net worth customers and their immediate families with a relationship manager, wealth advice and solutions. Customers can access emergency travel assistance, telephone banking and an online global view of their Premier accounts globally with free money transfers between them. HSBC Advance provides a range of preferential products and services customized to meet local needs. With a telephone service, access to wealth advice and online tools to support financial planning, it gives customers an online global view of their Advance accounts with money transfers between them. Wealth Solutions & Financial Planning process designed for global individual customer needs to help its clients to protect, grow and manage their wealth through investment and wealth insurance products manufactured by in-house partners, including Global Asset Management, Global Markets and HSBC Insurance, and by selected third party providers. During 2010, PFS provided 92 million individual and self-employed customers with financial services in over 60 markets globally.

Commercial Banking

The Company ! segments ! its CMB business into Corporate, to serve both Corporate and Mid-Market companies, and Business Banking, to serve the small and medium-sized enterprises (SME��) sector. It provides support to companies as they expand both domestically and internationally, and ensures a focus on the business banking segments. It offers a range of financing, both domestic and cross-border, including overdrafts, receivables finance, term loans and syndicated, leveraged, acquisition and project finance. Asset finance is offered in selected sites, focused on leasing and instalment finance for vehicles, plant and equipment. It is a provider of domestic and cross-border payments and collections, liquidity management and account services globally, delivered through its e-platform, HSBC net. It provides international trade products and services, to both buyers and suppliers, such as export finance, guarantees, documentary collections and forfeiting to improve efficiency and help mitigate risk throughout the supply chain.

CMB customers are volume users of its foreign exchange, derivatives and structured products. Capital markets & advisory is raising capital on debt and equity markets and provide advisory services. Commercial cards issuing helps customers enhance cash management, credit control and purchasing. Card acquiring services enable merchants to accept credit and debit card payments in person or remotely. CMB offers key person, employee benefits and a range of commercial risk insurance, such as property, cargo and trade credit. Direct channels include online and direct banking offerings, such as telephone banking, HSBCnet and Business Internet Banking.

Global Banking and Markets

GB&M provides tailored financial solutions to government, corporate and institutional clients and private investors globally. Managed as a global business, GB&M operates a long-term relationship management approach to build a understanding of clients��financial requirements. Sector-focused client service! teams co! nsisting of relationship managers and product specialists develop financial solutions to meet individual client needs. GB&M is managed as four principal business lines: Global Markets, Global Banking, Global Asset Management and Principal Investments.

Global Markets operations consist of treasury and capital markets services. Products include foreign exchange; currency, interest rate, bond, credit, equity and other derivatives; government and non-government fixed income and money market instruments; precious metals and exchange-traded futures; equity services; distribution of capital markets instruments, and securities services, including custody and clearing services and funds administration to both domestic and cross-border investors. Global Banking offers financing, advisory and transaction services. Its products include capital raising, advisory services, bilateral and syndicated lending, leveraged and acquisition finance, structured and project finance, lease finance and non-retail deposit taking; international, regional and domestic payments and cash management services; and trade services for large corporate clients.

Global Asset Management offers investment solutions to institutions, financial intermediaries and individual investors globally. Principal Investments includes its relationships with third-party private equity managers and other investments. GB&M is a global business, which provides financial solutions to government, corporate and institutional clients globally.

Global Private Banking

GPB works with the Company�� high net worth clients to offer ways to manage and preserve wealth. HSBC Private Bank is the principal marketing name of its international private banking business, GPB. GPB works with its clients to offer both ways to manage and preserve wealth while optimising returns. GPB accesses six advisory centers in Hong Kong, Singapore, Geneva, New York, Paris and London. Private Banking services consist of multi-currency depo! sit accou! nts and fiduciary deposits, credit and specialist lending, treasury trading services, cash management, securities custody and clearing. GPB works to ensure that its clients have access to other products and services available in HSBC, such as credit cards, Internet banking, corporate banking and investment banking.

Private Wealth Management consists of both advisory and discretionary investment services. A range of investment vehicles is covered, including bonds, equities, derivatives, options, futures, structured products, mutual funds and alternatives (hedge funds, private equity and real estate). Corporate Finance Solutions helps provide clients with solutions for their companies, working in conjunction with GB&M. Private Wealth Solutions consist of planning, trustee and other fiduciary services to protect wealth and preserve it for future generations. Its expertise includes trusts, foundation and company administration, charitable trusts and foundations, insurance, family office advisory and philanthropy.

Other

The Company�� Other contains the results of certain property transactions and unallocated investment activities. It also includes centrally held investment companies, movements in fair value of own debt, HSBC�� holding company and financing operations.

Advisors' Opinion:

• [By David O��ara]

  HSBC
  At current prices,�HSBC� (LSE: HSBA  ) (NYSE: HBC  ) makes up 7.8% of the FTSE 100. It shares have the most influence on the FTSE 100.

• [By Sara Sjolin]

  Banks weighed on the indexes, with shares of Commerzbank AG (DE:CBK) 2.9% lower in Frankfurt, Cr茅dit Agricole SA (FR:ACA) �down 2% in Paris and HSBC Holdings PLC (UK:HSBA) � (HBC) � (HK:5) �off 1.2% in London.

• [By G. A. Chester]

  Today, I'm putting banking behemoth�HSBC Holdings� (LSE: HSBA  ) (NYSE: HBC  ) under the microscope.

  Dividend history
  Three main events have affected on HSBC shareholders' dividends over the last 15 years:

• [By Andrew Marder]

  The banks facing the first wave of investigation are Barclays (NYSE: BCS  ) , Royal Bank of Scotland (NYSE: RBS  ) , HSBC (NYSE: HBC  ) , and Lloyds Banking Group (NYSE: LYG  ) . These companies are going to pay out something, as they've already admitted that rules were broken. The question remains -- how much will it cost?